Ipsen news | Ipsen Global

Stories

Discover all of the trending stories of Ipsen Group.

Explore more by category

Filter

Period

Filter by

recent search

Showing: 15 of 160 stories

Lily May's Story: Living With a Pediatric Low-Grade Glioma
 • 3 mins read

 – 3 mins read

Lily May’s Story: Living With a Pediatric Low-Grade Glioma

Lily May, a vibrant and determined seven-year-old, loves gymnastics and golf. Yet, like many children living with pediatric low-grade glioma (pLGG), her life has been profoundly shaped by this rare brain tumor. Although the global burden is unknown, pLGG is a rare childhood brain tumor.


Recognizing the Signs Early: Improving Outcomes for Children with Rare Liver Diseases 
 • 2 mins read

 – 2 mins read

Recognizing the Signs Early: Improving Outcomes for Children with Rare Liver Diseases 

Professor Björn Fischler, paediatric hepatologist at the Karolinska Institute in Sweden, and Laure Dorey, Director of the French patient organisation AMFE and mother of a child living with biliary atresia (BA), together discussed the realities of living with rare liver diseases (RLDs).


Beyond tired: Understanding fatigue in Primary Biliary Cholangitis
 • 1 mins read

 – 1 mins read

Beyond tired: Understanding fatigue in Primary Biliary Cholangitis

Fatigue is a distinct and debilitating condition that can have a significant impact on quality of life…


Understanding PBC: Managing what Matters Most 
 • 2 mins read

 – 2 mins read

Understanding PBC: Managing what Matters Most 

Ipsen’s Sandra Silvestri sat down with Dr. Laura Cristoferi, Professor Mark Swain, and Professor David Jones to explore the latest evidence on management of the rare, autoimmune disease, primary biliary cholangitis (PBC).


H1 Results: a strong first half of 2025 
 • 1 mins read

 – 1 mins read

H1 Results: a strong first half of 2025 

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our therapeutic areas — Rare Disease, Oncology, and Neuroscience — reflecting the strength of our strategy and the dedication of our teams.